The approved indications for bevacizumab and VEGFR2 tyrosine kinase inhibitor (TKI) are similar for CRC and RCC, but different for breast cancer, HCC, NSCLC, GBM, DTC, MTC and STS. Here, KDR is linked to renal cell carcinoma.